Compile Data Set for Download or QSAR
maximum 50k data
Found 46 of ic50 for UniProtKB: P00533
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM537926(US11248003, Example 1)
Affinity DataIC50:  0.400nMAssay Description:The inhibitory activity on a C797S-containing epidermal growth factor receptor (EGFR) kinase and an MET kinase was measured for compound 1 obtained i...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM547941(WO2022090481, Example I-162)
Affinity DataIC50:  1.10nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM112499(DACOMITINIB | US8623883, No. 2 | WO2022090481, Exa...)
Affinity DataIC50:  1.60nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM50322823((S)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahy...)
Affinity DataIC50:  1.90nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM5447(CHEMBL939 | GEFITINIB | Iressa | N-(3-Chloro-4-flu...)
Affinity DataIC50:  2.5nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM547965(WO2022090481, Example I-186)
Affinity DataIC50:  2.60nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM5446(CHEMBL553 | ERLOTINIB HYDROCHLORIDE | Erlotinib | ...)
Affinity DataIC50:  3nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM547940(WO2022090481, Example I-161)
Affinity DataIC50:  3nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM547983(WO2022090481, Example I-204)
Affinity DataIC50:  3.5nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM547807(WO2022090481, Example I-022 | WO2022090481, Exampl...)
Affinity DataIC50:  5nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625598(US20230322822, Compound 14)
Affinity DataIC50:  5.70nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM547888(WO2022090481, Example I-107)
Affinity DataIC50:  7.07nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625597(US20230322822, Compound 12)
Affinity DataIC50:  9.80nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625600(US20230322822, Compound 32)
Affinity DataIC50:  10.5nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625596(US20230322822, Compound 11)
Affinity DataIC50:  10.7nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625592(US20230322822, Compound 2)
Affinity DataIC50:  13.8nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625591(US20230322822, Compound 1)
Affinity DataIC50:  19.8nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625597(US20230322822, Compound 12)
Affinity DataIC50:  29.3nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625594(US20230322822, Compound 6)
Affinity DataIC50:  33.8nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625591(US20230322822, Compound 1)
Affinity DataIC50:  39.9nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625599(US20230322822, Compound 24)
Affinity DataIC50:  41.6nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625599(US20230322822, Compound 24)
Affinity DataIC50:  41.6nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625595(US20230322822, Compound 9)
Affinity DataIC50:  41.9nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625598(US20230322822, Compound 14)
Affinity DataIC50:  43.9nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625592(US20230322822, Compound 2)
Affinity DataIC50:  48.1nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625593(US20230322822, Compound 5)
Affinity DataIC50:  50nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625594(US20230322822, Compound 6)
Affinity DataIC50:  51nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625600(US20230322822, Compound 32)
Affinity DataIC50:  51.6nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625610(US20230322822, Compound 30)
Affinity DataIC50:  55.6nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625609(US20230322822, Compound 29)
Affinity DataIC50:  57.8nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625605(US20230322822, Compound 13)
Affinity DataIC50:  60.1nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625596(US20230322822, Compound 11)
Affinity DataIC50:  66.1nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625593(US20230322822, Compound 5)
Affinity DataIC50:  73.7nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625606(US20230322822, Compound 23)
Affinity DataIC50:  79.6nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625604(US20230322822, Compound 4)
Affinity DataIC50:  80.6nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625608(US20230322822, Compound 28)
Affinity DataIC50:  85.2nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50:  177nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM50185140(AP-26113 | Brigatinib | US11248003, Example Brigat...)
Affinity DataIC50:  178nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625601(US20230322822, Control compound 1)
Affinity DataIC50:  184nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625603(US20230322822, Control compound 3)
Affinity DataIC50:  203nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625601(US20230322822, Control compound 1)
Affinity DataIC50: >250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM625603(US20230322822, Control compound 3)
Affinity DataIC50: >250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: >250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM50029668(AZD-9291 | Osimertinib | US10085983, Compound AZD-...)
Affinity DataIC50:  513nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM50029668(AZD-9291 | Osimertinib | US10085983, Compound AZD-...)
Affinity DataIC50:  626nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Homo sapiens (Human))
Oncobix

US Patent
LigandPNGBDBM50160870(CHEMBL3787344 | US11896597, Compound EGF816 | WO20...)
Affinity DataIC50:  745nMAssay Description: This assay quantifies the phosphorylation of EGFR at Tyr1068 and was used to measure the inhibitory effect of compounds on the transgenic EGFR del19...More data for this Ligand-Target Pair
In DepthDetails PubMed